Healthy persons
Conditions
Interventions
Ingestion of 4 capsules per day of either plasmalogen (0.5 mg per capsule) or placebo for a period of 4 weeks.
plasmalogen, 4 weeks
Sponsors
Fujino Minoru
Ogaki Tetsuro
Fujino Takehiko
The Japanese Plasmalogen Society
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: To meet all of the three conditions: 1) male students belonging to sport clubs of Kyushu Sangyo University; 2) unmarried men aged 18-22 years at the time of provision of informed consent; and 3) those who are able to provide wriiten informed consent.
Exclusion criteria
Exclusion criteria: To meet at least one of the following conditions: 1) those under medical treatment; 2) those who are participating in an other clinical trial; 3) those with shellfish allergy 4) those who are judged as ineligible by a principal physican investigator or a designated supervising investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| T score of the total distrubance of mood (TDM) score of the Profile of Mood State (POMS2). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) seven scales of POMS2; 2) Athene Insomnia Scale; 3) brain fatigue measurements including Brain-Fatigue Score Questionnaire and Kraepeline test; 4) exercise performance including VO2max, muscle strength, and power; 5) plasmalogens in plasma and erythrocytes; 6) blood concentrations of brain derived neurotrophic factor (BDNF) and adiponectin; 7) urinaruy 8-hydroxy deoxy quanine (8-OHdG); 8) body mass index and percent fat; 9) daily variation of mental and physical condition assessed by a smartphone application; and 10) 24-hour heart rate variation (those with a specified consent only). | — |
Contacts
Public ContactTetsuro Ogaki
Kyushu Sangyo University
Outcome results
None listed